TEAM

AURORA

SPENCER GUTHRIE

CEO

 

Spencer brings significant expertise with over 20 years in drug development and commercialization experience across large, small and start-up biotech. He has spent more than 12 years of his career on amyloid-related diseases, with 5 years leading clinical teams in Phase 2 and 3 Alzheimer’s studies with Elan and Jansen. Prior to Aurora Bio, he was head of Development Operations and Medical Affairs for Prothena Biosciences tasked with leading programs in AL and ATTR Amyloidosis as well as Parkinsons’s Disease. He was Head of Global Strategy for the TEGSEDI launch for ATTR amyloidosis working with Ionis and at Akcea. He has over 30 published articles on amyloid diseases.

JONATHAN WALL

CSO

 

Jonathan Wall is a Professor at University of Tennessee Medical Center, Knoxville and Head of the Amyloidosis and Cancer Theranostics Program. Jonathan is an internationally known expert in the field of amyloidosis, has worked in amyloid based research for over 20 years. He has over 100 publications and more than 13 issued US patents in this field. His research work was instrumental in the development of multiple antibody-based therapeutics that have undergone clinical development by biotech companies. His lab has received over $10M in NIH grant and contract funding for work that focuses on the development and translation of novel diagnostic and therapeutic reagents for amyloidosis.  

NANCY MILLER-RICH

Executive Strategic Advisor

  • A biotech executive with >35 years of commercial and BD experience.

  • Current Board Membership: Intercept, UDG Healthcare, TB Alliance, Gavilan Biodesign

  • Former: Sr VP, Head of BD for Merck: Executive roles at Schering Plough and Sandoz

SCIENTIFIC ADVISORY BOARD

JEFF KELLY

PhD, Scripps Research Institute

Jeffery W. Kelly is Professor of Chemistry at The Scripps Research Institute. He is a leading expert in protein misfolding disorders and discovered the first approved drug (tafamidis vyndaqel; Pfizer) for
transthyretin amyloidosis

  • Co-founder of FoldRx (acquired by Pfizer) and Proteostasis

  • Board of Directors: Yumanity, Proteostasis, Scripps, George Hewitt Foundation, Amyloidosis Research
    Consortium

MORIE GERTZ

MD, Mayo Clinic

Dr. Gertz is Professor of the Art of Medicine and Chair Emeritus of the Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota. He is one of the world-leading hematologists in plasma cell disorders and is a world-renowned expert in amyloidosis He has worked in amyloidosis >30 years and has published over 700 articles.

MATHEW MAURER

MD, Columbia University/

New York Presbyterian

​​

Dr. Maurer is Professor of Cardiology at Columbia University, College of Physicians and Surgeons, where directs the Clinical Cardiovascular Research Laboratory at the Allen Hospital of New York Presbyterian Hospital. He is a world-renowned expert in cardiac amyloidosis. He has published over 200 articles and was co-chair of the Steering Committee of the ATTR ACT trial (pivotal trial for tafamidis

© 2019 Aurora Bio, All Rights Reserved